We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+18.29%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$250M
AUM Growth
-$27.1M
Cap. Flow
-$42M
Cap. Flow %
-16.77%
Top 10 Hldgs %
58.37%
Holding
52
New
6
Increased
8
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
ALGS icon
Aligos Therapeutics
ALGS
+$5.46M
2
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$5.2M
3
SEEL
Seelos Therapeutics, Inc. Common Stock
SEEL
+$4.88M
4
GHRS icon
GH Research
GHRS
+$3.06M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$2.84M

Top Sells

Rank Stock Value
1
ETNB
89bio
ETNB
+$9.32M
2
CRIS icon
Curis
CRIS
+$8.69M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$7.11M
4
MRSN
Mersana Therapeutics
MRSN
+$5.79M
5
ALT icon
Altimmune
ALT
+$5.75M

Sector Composition

Rank Sector Weight
1 Healthcare 87.44%
2 Financials 5.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIL
51
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-661,565
Closed -$7.11M
VINCW
52
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
– –
-520,000
Closed -$2.1M
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Acuta Capital Partners held 52 positions worth $250M, down 9.8% from $277M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Acuta Capital Partners withdrew a net $42M in Q2 2021, closing 14 positions and reducing 20 holdings. Its most notable exit was 89bio, an estimated $9.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 91% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Aligos Therapeutics worth $4.37M.

  • Acuta Capital Partners's largest Q2 2021 buy was Aligos Therapeutics: 8,570 shares worth $4.37M.
  • Acuta Capital Partners added most to Seelos Therapeutics, Inc. Common Stock in Q2 2021, an estimated $4.88M increase.
  • Acuta Capital Partners's biggest Q2 2021 reduction was Sage Therapeutics, cutting an estimated $4.78M.
  • Acuta Capital Partners fully exited 89bio in Q2 2021, selling an estimated $9.32M.
  • Acuta Capital Partners's ten largest holdings make up 58% of its $250M portfolio in Q2 2021.
  • Acuta Capital Partners opened 6 new positions and closed 14 in Q2 2021.
  • Acuta Capital Partners's portfolio value fell 9.8% quarter-over-quarter to $250M.

Based on Acuta Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.